To test the effect of TIM-3, LAG-3 and 2B4 disruption in tumor-specific T cells upon antigen recognition on cancer cells expressing IR ligands, we challenged TCRED-IRCOMP and TCRED-IRKO T cells with either U266 (a cell line naturally expressing HLA-A2 and NY-ESO-1) or MM1.s transduced to express HLA-A2 and NY-ESO-1 antigen and luciferase (MM1.s A2posESO-1pos, Supplementary Figures 3C, D). The gene discussed is LAG3; the disease is neoplasm.